News

KYORIN Pharmaceutical Co., Ltd. announced that it has entered into a license agreement on November 9, 2026, with Edesa Biotech, Inc. (Toronto, Canada, CEO: Par Nijhawan), for Edesa's ARDS treatment EB05 (paridiprubart).
Under this agreement, KYORIN has obtained the exclusive rights to develop and commercialize EB05 in Japan. KYORIN will make an upfront payment of USD 12 million to Edesa, along with milestone payments of up to USD 134 million based on the progress of development, NHI price listing, and the achievement of certain net sales targets. Additionally, royalties based on net sales will be paid to Edesa.
ARDS is a severe, life-threatening form of acute respiratory failure resulting from conditions such as pneumonia, sepsis, trauma and other serious conditions. Current management is primarily supportive, including mechanical ventilation, and there are limited pharmacologic treatment options shown to improve survival. Thus, ARDS continues to be associated with substantial mortality and represents a significant unmet medical need.
Paridiprubart is an investigational monoclonal antibody targeting Toll-like receptor 4 (TLR4), a key mediator of innate immune signaling and inflammation. By inhibiting TLR4 signaling, paridiprubart is designed to modulate excessive inflammatory responses that contribute to the pathophysiology of ARDS - with the goal of improving survival and clinical outcomes. Edesa and KYORIN intend to collaborate on future clinical development of EB05 in ARDS, with KYORIN responsible for clinical development activities in Japan.
KYORIN aims to create high-value new drugs that meet medical needs and has prioritized the "Expansion of development pipeline through in-licensing" under its medium-term vision, "Vision 110－Stage2－". Through this agreement, we are committed to actively advancing development to deliver new treatment options to patients as soon as possible, thereby contributing to people's health.